Skip to content

ADAS 3D v2.9

by ADAS3D Medical S.L.

ADAS 3D v2.9 is a surgical simulation system (FDA Class II; FDA product code LLZ, System, Image Processing, Radiological) made by ADAS3D Medical S.L., cleared under FDA 510(k) K210850 on 5 Apr 2021 and listed in FDA GUDID since 9 Mar 2022 (UDI-DI 08437021722055), active as of 23 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 23 Oct 2026

Documents

510(k) K210850

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number08437021722055 UDI-DI Date9 Mar 2022ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k) from GUDID NumberK210850 Date5 Apr 2021IssuedStatusActive

Official records

Across registries

2 registries list this device

  • FDA 510(k) K210850 decided 5 Apr 2021 Active
  • FDA GUDID UDI-DI 08437021722055 listed 9 Mar 2022 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K210850
  2. Listed FDA GUDID 08437021722055

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
Adas 3D
Generic name
Surgical simulation system
Model / reference
v2.9
Primary DI / UDI-DI
08437021722055
510(k) Number
FDA product code
LLZ
GMDN term
Surgical simulation system
Device class
Class II
Regulation number
892.2050
GUDID distribution status
In Commercial Distribution

Similar devices

Other devices filed under FDA product code LLZ (System, Image Processing, Radiological).

Other devices from ADAS3D Medical S.L.

  • Adas 3D 2.14.1

    Class II
  • Adas 3D

    Class II
  • Adas 3D V2.8

    Class II
  • Adas 3D V2.6

    Class II

See all devices from ADAS3D Medical S.L. →

Properties

  • Prescription use
  • Manufacturing date
Other properties (13, all answered No)